Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Clinical trial NCT06772623 · RECRUITING
Trial details
- NCT number
- NCT06772623
- Sponsor
- AbbVie
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-06
- Primary completion
- 2027-11-01
- Enrollment
- 252
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.